Monday, June 17, 2024

The Association between Cannabis Product Characteristics and Symptom Relief

Share


  • 1.

    Piper, B. J. et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 31, 569–575 (2017).

    Article 

    Google Scholar 

  • 2.

    Hill, K. P. & Weiss, R. D. Minimal physical health risk associated with long-term cannabis use—but buyer beware. JAMA. 315, 2338–2339 (2016).

    Article 

    Google Scholar 

  • 3.

    Rubin, R. Medical marijuana is legal in most states, but physicians have little evidence to guide them. JAMA. 317, 1611–1613 (2017).

    Article 

    Google Scholar 

  • 4.

    National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press (US) (2017).

  • 5.

    Stith, S. S. & Vigil, J. M. V. Federal barriers to Cannabis research. Science. 352, 1182 (2016).

    ADS 
    CAS 
    Article 

    Google Scholar 

  • 6.

    Di Forti, M. et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet Psychiatry. 2, 233–238 (2015).

    Article 

    Google Scholar 

  • 7.

    Gage, S. H. et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychological Medicine. 47, 971–980 (2017).

    CAS 
    Article 

    Google Scholar 

  • 8.

    Fakhoury, M. Could cannabidiol be used as an alternative to antipsychotics? Journal of Psychiatric Research. 80, 14–21 (2016).

    Article 

    Google Scholar 

  • 9.

    Gururajan, A. & Malone, D. T. Does cannabidiol have a role in the treatment of schizophrenia? Schizophrenia Research. 176, 281–290 (206).

  • 10.

    Iseger, T. A. & Bossong, M. G. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research. 162, 153–161 (2015).

    Article 

    Google Scholar 

  • 11.

    Christian, D. et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research. 130, 216–221 (2011).

    Article 

    Google Scholar 

  • 12.

    National Institute of Drug Abuse. Marijuana as Medicine, https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine on (2018).

  • 13.

    Ramo, D. E., Popova, L., Grana, R., Zhao, S. & Chavez, K. Cannabis Mobile Apps: A Content Analysis. Eysenbach G, ed. JMIR mHealth and uHealth. 3, e81 (2015).

    Google Scholar 

  • 14.

    ReleafApp, https://releafapp.com/ (2018).

  • 15.

    Vigil, J. M., Stith, S. S., Adams, I. M. & Reeve, A. P. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS ONE. 12, e0187795 (2017).

    Article 

    Google Scholar 

  • 16.

    Kindred, J. H. et al. Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation. Complementary Therapies in Medicine. 33, 99–104 (2017).

    Article 

    Google Scholar 

  • 17.

    Bonn-Miller, M. O., Babson, K. A. & Vandrey, R. Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug and Alcohol Dependence. 136, 162–165 (2014).

    Article 

    Google Scholar 

  • 18.

    Costain, W. F. The effects of cannabis abuse on the symptoms of schizophrenia: Patient perspectives. International Journal of Mental Health Nursing. 17, 227–235 (2008).

    Article 

    Google Scholar 

  • 19.

    MacCallum, C. A. & Russo, E. B. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 49, 12–19 (2018).

    CAS 
    Article 

    Google Scholar 

  • 20.

    Fischer, B. et al. Lower-risk cannabis use guidelines: A comprehensive update of evidence and recommendations. American Journal of Public Health. 107, e1–e12 (2017).

    Article 

    Google Scholar 

  • 21.

    Stith, S. S., Vigil, J. M., Brockelman, F., Keenan, K. & Hall, B. Patient-reported symptom relief following medical cannabis consumption. Frontiers in Pharmacology. 9, 916, https://www.frontiersin.org/articles/10.3389/fphar.2018.00916/full (2018).

  • 22.

    Vigil, J. M. et al. Effectiveness of raw, natural medical Cannabis flower for treating insomnia under naturalistic conditions. Medicines. 5, 75. https://www.mdpi.com/2305-6320/5/3/75 (2018).

  • 23.

    Blundell, M., Dargan, P. & Wood, D. A cloud on the horizon-a survey into the use of electronic vaping devices for recreational drug and new psychoactive substance (NPS) administration. QJM. 111, 9–14 (2018).

    CAS 
    Article 

    Google Scholar 

  • 24.

    Eggers, M. E. et al. Youth use of electronic vapor products and blunts for administering cannabis. Addictive Behaviors. 70, 79–82 (2017).

    Article 

    Google Scholar 

  • 25.

    Marijuana Policy Project, https://www.mpp.org/issues/medical-marijuana/state-by-state-medical-marijuana-laws/medical-marijuana-patient-numbers/ (2018).

  • 26.

    Dinis-Oliveira, R. J. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metabolism Reviews. 48, 80–87 (2016).

    CAS 
    Article 

    Google Scholar 

  • 27.

    Lefever, T. W. et al. Vaping synthetic cannabinoids: A novel preclinical model of e-cigarette use in mice. Substance Abuse: Research and Treatment. 11, https://doi.org/10.1177/1178221817701739 (2017).

  • 28.

    Manwell, L. A. et al. A vapourized Δ9-tetrahydrocannabinol (Δ9-THC) delivery system part I: Development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. Journal of Pharmacological and Toxicological Methods. 70, 120–127 (2014).

    CAS 
    Article 

    Google Scholar 

  • 29.

    Nguyen, J. D. et al. Inhaled delivery of Δ9-tetrahydrocannabinol (THC) to rats by e-cigarette vapor technology. Neuropharmacology. 109, 112–120 (2016).

    CAS 
    Article 

    Google Scholar 

  • 30.

    Vandrey, R. et al. Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. Journal of Analytical Toxicology. 41, 83–99 (2017).

    CAS 
    Article 

    Google Scholar 

  • 31.

    Varlet, V. et al. Drug vaping applied to cannabis: Is “Cannavaping” a therapeutic alternative to marijuana? Scientific Reports. 6, 25599, https://www.nature.com/articles/srep25599 (2016).

  • 32.

    Cohen, N. L., Heinz, A. J., Ilgen, M. & Bonn-Miller, M. O. Pain, Cannabis Species, and Cannabis Use Disorders. Journal of Studies on Alcohol and Drugs. 77, 515–520 (2016).

    Article 

    Google Scholar 

  • 33.

    Pearce, D., Mitsouras, K. & Irizarry, K. Discriminating the Effects of Cannabis sativa and Cannabis indica: A Web Survey of Medical Cannabis Users. Journal of Alternative & Complementary Medicine. 20, 787–791 (2014).

    Article 

    Google Scholar 

  • 34.

    Andreae, M. H. et al. Inhaled cannabis for chronic neuropathic pain: an individual patient data meta-analysis. The Journal of Pain. 16, 1221–1232 (2015).

    Article 

    Google Scholar 

  • 35.

    Mücke, M., Phillips, T., Radbruch, L., Petzke, F. & Häuser, W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 3, Art. No.: CD012182. https://doi.org/10.1002/14651858.CD012182.pub2 (2018).

  • 36.

    Belendiuk, K. A., Babson, K. A., Vandrey, R. & Bonn-Miller, M. O. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addictive Behaviors. 50, 178–181 (2015).

    Article 

    Google Scholar 

  • 37.

    Bonn-Miller, M. O. et al. Labeling accuracy of cannabidiol extracts sold online. JAMA. 318, 1708–1709 (2017).

    Article 

    Google Scholar 

  • 38.

    Burstein, S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic & Medicinal Chemistry. 23, 1377–1385 (2017).

    Article 

    Google Scholar 

  • 39.

    McPartland, J. M., Duncan, M., Di Marzo, V. & Pertwee, R. G. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology. 172, 737–753 (2015).

    CAS 
    Article 

    Google Scholar 

  • 40.

    Piano, M. Cannabis smoking and cardiovascular health: It’s complicated. Clin. Pharmacol. Ther. 102, 191–193 (2017).

    CAS 
    Article 

    Google Scholar 

  • 41.

    Richards, J. R. Cannabinoid hyperemesis syndrome: Pathophysiology and treatment in the emergency department. Journal of Emergency Medicine. 54, 354–363 (2018).

    Article 

    Google Scholar 

  • 42.

    Fowler, C. Delta9-tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature. Clin. Pharmacol. Ther. 97, 587–596 (2015).

    CAS 
    Article 

    Google Scholar 

  • 43.

    Śledziński, P., Zeyland, J., Słomski, R. & Nowak, A. The current state and future perspectives of cannabinoids in cancer biology. Cancer Medicine. 7, 765–775 (2018).

    Article 

    Google Scholar 



  • Source link

    Subscribe
    Notify of
    guest

    0 Comments
    Inline Feedbacks
    View all comments

    Read more

    Search more

    Latest News